Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

  • Post published:October 30, 2020
  • Post category:Press Release
Read more about the article Mind Medicine MindMed : MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Mind Medicine MindMed : MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

  • Post published:October 16, 2020
  • Post category:Press Release
Read more about the article MindMed Announces $25 Million Bought Deal Public Offering

MindMed Announces $25 Million Bought Deal Public Offering

  • Post published:October 9, 2020
  • Post category:Press Release
Read more about the article MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

  • Post published:October 5, 2020
  • Post category:Press Release
Read more about the article MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

  • Post published:September 24, 2020
  • Post category:Press Release
Read more about the article MindMed Confirms No Material Change

MindMed Confirms No Material Change

  • Post published:September 23, 2020
  • Post category:Press Release
Read more about the article BREAKING: MindMed Applies to List on Nasdaq

BREAKING: MindMed Applies to List on Nasdaq

  • Post published:September 21, 2020
  • Post category:News
Read more about the article MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

  • Post published:August 25, 2020
  • Post category:Press Release
Read more about the article Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

  • Post published:August 19, 2020
  • Post category:Clinical Trials/News
Read more about the article Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

  • Post published:August 14, 2020
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More